HomeCompareSMDCF vs ARCC

SMDCF vs ARCC: Dividend Comparison 2026

SMDCF yields 5.83% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SMDCF wins by $4.8K in total portfolio value· pulled ahead in Year 2
10 years
SMDCF
SMDCF
● Live price
5.83%
Share price
$17.15
Annual div
$1.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.4K
Annual income
$845.74
Full SMDCF calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — SMDCF vs ARCC

📍 SMDCF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSMDCFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SMDCF + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SMDCF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SMDCF
Annual income on $10K today (after 15% tax)
$495.63/yr
After 10yr DRIP, annual income (after tax)
$718.88/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, SMDCF beats the other by $717.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SMDCF + ARCC for your $10,000?

SMDCF: 50%ARCC: 50%
100% ARCC50/50100% SMDCF
Portfolio after 10yr
$27.0K
Annual income
$423.45/yr
Blended yield
1.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

SMDCF
No analyst data
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SMDCF buys
0
ARCC buys
0
No recent congressional trades found for SMDCF or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSMDCFARCC
Forward yield5.83%10.82%
Annual dividend / share$1.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$29.4K$24.5K
Annual income after 10y$845.74$1.16
Total dividends collected$7.2K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: SMDCF vs ARCC ($10,000, DRIP)

YearSMDCF PortfolioSMDCF Income/yrARCC PortfolioARCC Income/yrGap
1$11,283$583.09$11,381$541.15$98.00ARCC
2← crossover$12,688$614.87$12,621$284.08+$67.00SMDCF
3$14,222$646.18$13,827$145.31+$395.00SMDCF
4$15,895$676.94$15,062$73.43+$833.00SMDCF
5$17,714$707.05$16,364$36.89+$1.4KSMDCF
6$19,691$736.44$17,757$18.49+$1.9KSMDCF
7$21,834$765.06$19,258$9.25+$2.6KSMDCF
8$24,155$792.84$20,880$4.63+$3.3KSMDCF
9$26,666$819.74$22,636$2.32+$4.0KSMDCF
10$29,378$845.74$24,539$1.16+$4.8KSMDCF

SMDCF vs ARCC: Complete Analysis 2026

SMDCFStock

SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. It also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. The company offers its telemedicine services and devices to subscribers using telephonic and internet communication technology. It serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. The company has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and collaboration agreement with the Hebrew University of Jerusalem and the Hadassah Medical Center to develop an artificial intelligence tool for predicting future life-threatening cardiac events based on 12 Lead ECG monitoring. SHL Telemedicine Ltd. was founded in 1987 and is headquartered in Tel Aviv, Israel.

Full SMDCF Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this SMDCF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SMDCF vs SCHDSMDCF vs JEPISMDCF vs OSMDCF vs KOSMDCF vs MAINSMDCF vs HTGCSMDCF vs GBDCSMDCF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.